Neoadjuvant Chemotherapy With or Without Metformin in Early Breast Cancer.

Neoadjuvant Chemotherapy With or Without Metformin in Early Breast Cancer.

Metformin is a widely used anti-diabetic drug. Several studies have pointed out a potentially beneficial effect of metformin therapy in diabetic cancer patients. Several studies are investigating the anti-tumor effect of metformin in early breast cancer. However, the enhancing effect of metformin on anti-tumor immunity has only been demonstrated in animal models. This study examines the immune effect of metformin in breast cancer patients treated with preoperative chemotherapy.

Inclusion Criteria:

• Histologically proven breast carcinoma.
• American Society of Anesthesiology (ASA) score I-II.
• Candidate for neoadjuvant chemotherapy as per hospital's protocol.
• Clinically measurable tumor.
• No evidence of distant metastasis.
• Normal renal and liver functions.
• Non-diabetics.

Exclusion Criteria:

• Pregnant or lactating women.
• Metastatic breast cancer patients.
• Patients with hepatic impairment.
• Patients with renal impairment.
• Diabetics.
• Patients unwilling to participate or withdrawing from the trial.
• Psychological/ mental impairment.